lineage,string,ID
B.1.1.7,"The Alpha strain (B.1.1.7) was first detected in the United Kingdom in November of 2020, and infections spiked in December of that year [93].",PMC9230982
B.1.351,The variant formerly known as the ‘South Africa variant’ is now known as the Beta variant (B.1.351) or 20H/501Y.V2 in the Nextstrain database and GH/501Y.V2 in the GISAID database [94].,PMC9230982
P.1,"For Pfizer, Moderna, and AstraZeneca vaccinations, neutralization was projected to be reduced by 5- to 10-fold, whereas Johnson & Johnson vaccine neutralization was reduced by more than 10-fold..

Gamma (P.1) is another VOC, and it is defined as B.1.1.28.1.",PMC9230982
B.1.617.2,"The Delta variant (B.1.617.2) was detected for the first time in India in October 2020, and by December 2021, it had become the widely dominant variant, remaining so until January 2022 [219].",PMC9230982
B.1.617,"Two mutations in the receptor-binding domain of B.1.617 (Delta), which interacts with the ACE2 receptor and is the primary target of neutralizing antibodies, are present in the spike protein of B.1.617 (Delta).",PMC9230982
B.1.1.529,"The World Health Organization (WHO) classified Omicron (B.1.1.529) as the fifth SARS-CoV-2 VOC on 26 November 2021 [282,283].",PMC9230982
B.1,"(2021) found that in comparison to the wild-type (B.1) strain, the Delta variant affected a higher proportion of younger age groups, particularly those younger than 20 years (0–9 years: 4.47% vs. 2.3%, 10–19 year: 9% vs. 7%) [405]..",PMC9230982
A.2.2,"Our simulations showed that one infected agent with the ancestral (A.2.2) variant has a 14% chance of crossing a threshold of sustained community transmission (SCT) (i.e., > 5 infections per day, more than 3 days in a row), assuming no change in the prevailing preventative and counteracting policies.",PMC9012253
B.1.617.2,"However, one agent carrying the alpha (B.1.1.7) variant has a 43% chance of crossing the same threshold; a threefold increase with respect to the ancestral strain; while, one agent carrying the delta (B.1.617.2) variant has a 60% chance of the same threshold, a fourfold increase with respect to the ancestral strain.",PMC9012253
B.1.1.7,"However, one agent carrying the alpha (B.1.1.7) variant has a 43% chance of crossing the same threshold; a threefold increase with respect to the ancestral strain; while, one agent carrying the delta (B.1.617.2) variant has a 60% chance of the same threshold, a fourfold increase with respect to the ancestral strain.",PMC9012253
B.1.617.1,"Variants such as the B.1.617.1 (or kappa) and B.1.617.2 (or delta) lineages that emerged in India have been shown to be up to 2.5 times more transmissible than the ancestral strain9,11–13.",PMC9012253
B.1.1.7,"This strain clade 201/501Y.V1, Pango lineage B.1.1.7, and GISAID clade are all recognized Alpha variant by various scientific names.",PMC9088647
B.1.351,"26
 There are three mutations of significant importance in the spike area of the lineage, B.1.351 genome, K417N, E484K, N501Y, and a further five spike mutations, L18F, D80A, D215G, R246I, A701V, that have so far raised little concern.",PMC9088647
P.1,"56
 Safety and immunogenicity study of a SARS‐CoV‐2 variant vaccine (mRNA‐1273.351) is currently ongoing sponsored by The National Institute of Allergy and Infectious Diseases (NIAID) (NCT04785144)..

Lineage P.1, frequently referred to as the gamma variant, is a cause of COVID‐19.",PMC9088647
P.2,Gamma variant is particularly found from the other Brazilian zeta variant (Lineage P.2).,PMC9088647
B.1.427,"These resembling variants, B.1.427 and B.1.429 (epsilon variant), were initially identified in California (USA).",PMC9088647
B.1.429,"These resembling variants, B.1.427 and B.1.429 (epsilon variant), were initially identified in California (USA).",PMC9088647
B.1.617,"B.1.617.2 (Delta variant) is a variant of lineage B.1.617 of SARS‐CoV‐2, which is the reason for India's second wave in this pandemic of COVID‐19.",PMC9088647
B.1.617.1,"83
 The B.1.617.1 strain is 6.8‐fold more resistant to neutralization by sera from COVID‐19 convalescent and Moderna and Pfizer vaccinated patients, according to a live virus experiment.",PMC9088647
C.1.2,"92
 Researchers discovered that this new C.1.2 variant is evolving and mutating at a faster pace inside its genome than other VOC or VOI along with the Delta variant.",PMC9088647
B.1.1.529,"K417N, N440K, G446S, S477N, T478K, E484A, Q493K, G496S, Q498R, N501Y, Y505H, and P681H are the most common spike protein mutations found in omicron variant.”
94
 According to preliminary laboratory findings, three doses of the Pfizer‐BioNTech COVID‐19 vaccine neutralize the Omicron variation (B.1.1.529 lineage), but two doses had much lower neutralization titers.",PMC9088647
B.1.1.7,"The variant derived from the SARS-CoV-2 20B clade was confirmed as B.1.1.7, now known as the Alpha variant.",PMC8920968
B.1.351,"The BNT162b2 vaccine (Pfizer) showed 0.81- to 1.46-fold reductions in geometric mean titers (GMTs) against mutations in B.1.1.7 and B.1.351 variants relative to the parental virus from Wuhan [112], [113].",PMC8920968
C.1,"The Beta variant (B 1.351) emerged in Nelson Mandela Bay, Eastern Cape, in October and November 2020 and soon became predominant in South Africa, overcoming the previously dominant variants B.1.1.54, B.1.1.56, and C.1 lineages [146].",PMC8920968
B.1.1.56,"The Beta variant (B 1.351) emerged in Nelson Mandela Bay, Eastern Cape, in October and November 2020 and soon became predominant in South Africa, overcoming the previously dominant variants B.1.1.54, B.1.1.56, and C.1 lineages [146].",PMC8920968
B.1.1.54,"The Beta variant (B 1.351) emerged in Nelson Mandela Bay, Eastern Cape, in October and November 2020 and soon became predominant in South Africa, overcoming the previously dominant variants B.1.1.54, B.1.1.56, and C.1 lineages [146].",PMC8920968
P.1,"The new VoC, the P.1 lineage, known today as the Gama variant, was detected in about 42% of the analyzed genomic sequences in samples from Manaus in December 2020 and presented important mutations with biological significance..",PMC8920968
B.1.617.2,"This uncommon infection of the Gamma variant in vaccinated people demands surveillance and studies of BNT162b2's effectiveness in regard to the Gamma variant..

First reported in India, in late December 2020, the double-mutated Delta VoC, a coronavirus variant formerly known as Indian VoC or B.1.617.2, is 40% more transmissible than the Alpha variant and two times more transmissible than the original Wuhan strain of SARS-CoV-2, leading to new lockdowns [176], [177].",PMC8920968
B.1.1.529,"This fact is intriguing to scientists worldwide, and the recommendation is for vaccinated people to continue taking precautions such as social distancing and wearing face masks..

On 24 November 2021, a new variant was identified in South Africa, variant B.1.1.529, later designated as Omicron by the WHO.",PMC8920968
B.1.617.2,"Currently designated variants of concern (VOCs) are B.1.1.7, B1.351, P.1, B.1.617.2 variants and B.1.1.529.",PMC8883582
P.1,"Currently designated variants of concern (VOCs) are B.1.1.7, B1.351, P.1, B.1.617.2 variants and B.1.1.529.",PMC8883582
B.1.1.7,"Currently designated variants of concern (VOCs) are B.1.1.7, B1.351, P.1, B.1.617.2 variants and B.1.1.529.",PMC8883582
B.1.1.529,"Coronaviruses are divided into four groups: Alpha (B.1.1.7), Beta (B1.351), Gamma (P.1), Delta (D.1) and Omicron (B.1.1.529).",PMC8883582
B.1.177,"Researchers from the field have identified eight global clades and classified them as S, O, L, V, G, GH, GR, and major lineages such as A, B, B.1, B.1.1, B.1.177, and B.1.1.7 have been identified (Koyama et al., 2020; Nayak et al., 2021).",PMC8883582
B.1.1,"Researchers from the field have identified eight global clades and classified them as S, O, L, V, G, GH, GR, and major lineages such as A, B, B.1, B.1.1, B.1.177, and B.1.1.7 have been identified (Koyama et al., 2020; Nayak et al., 2021).",PMC8883582
B.1,"Researchers from the field have identified eight global clades and classified them as S, O, L, V, G, GH, GR, and major lineages such as A, B, B.1, B.1.1, B.1.177, and B.1.1.7 have been identified (Koyama et al., 2020; Nayak et al., 2021).",PMC8883582
B.1.351,"Bamlanivimab and etesevimab, will expected stagger in efforts to improvement full FDA approval given the antiviral resistance observed against B.1.351, P.1.",PMC8883582
B.1.526,"and B.1.526 (Doggrell, 2021).",PMC8883582
B.1.617,"Sotrovimab has also shown efficacity against variant lineages B.1.1.7, B.1.351, P.1, B.1.617, B.1.427/B.1.429 and B.1.526.",PMC8883582
B.1.427,"Sotrovimab has also shown efficacity against variant lineages B.1.1.7, B.1.351, P.1, B.1.617, B.1.427/B.1.429 and B.1.526.",PMC8883582
B.1.1.529,"1
             The lineage B.1.1.529 (Omicron) harbors 15 mutations located in the RBD and 8 mutated residues in the NTD relative to the wildtype (WT) virus.",PPR453676
B.1.1.7,"Using pseudovirus-based neutralization assay, we assessed the cross-reactivity of neutralizing antibodies against the Wuhan-1 (WT), B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 (Delta), and B.1.1.529 (Omicron) variants.",PPR453676
B.1.617.2,"Using pseudovirus-based neutralization assay, we assessed the cross-reactivity of neutralizing antibodies against the Wuhan-1 (WT), B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 (Delta), and B.1.1.529 (Omicron) variants.",PPR453676
B.1.351,"Using pseudovirus-based neutralization assay, we assessed the cross-reactivity of neutralizing antibodies against the Wuhan-1 (WT), B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 (Delta), and B.1.1.529 (Omicron) variants.",PPR453676
B.1.1.529,"After the massive surge due to the delta (B·1·617·2) VoC, the emergence and rapid spread of the Omicron (B.1.1.529) VoC has further caused panic around the world.",PPR439656
B.1.617.2,Cells were incubated for 24 hours for ancestral (B.1) and Delta (B.1.617.2) variants and for 32 hours for Omicron variant.,PPR439656
B.1,Cells were incubated for 24 hours for ancestral (B.1) and Delta (B.1.617.2) variants and for 32 hours for Omicron variant.,PPR439656
A.2.2,"The neutralizing potential of these antibodies to inhibit viral infection and cytopathic effect, was first tested in vitro in HEK293 cells overexpressing ACE2 and TMRPSS2 (HEK-ACE2-TMPRSS2), utilizing the ancestral (A.2.2) SARS-CoV-2 strain, and also Beta and Delta variants.",PPR439367
B.1.1.7,"A number of SARS-CoV-2 lineages were defined as variants of concerns (VOCs) by the World Health Organization (WHO), including the B.1.1.7 (Alpha) lineage that arose in the UK26–30, B.1.351 (Beta) lineage in South Africa29–33, P.1 (Gamma) lineage in Brazil34, and B.1.617.2 (Delta) lineage in India35,36; while the B.1.617.1 (Kappa) variant was defined as a variant of interest (VOI)37–41.",PMC8688474
P.1,"A number of SARS-CoV-2 lineages were defined as variants of concerns (VOCs) by the World Health Organization (WHO), including the B.1.1.7 (Alpha) lineage that arose in the UK26–30, B.1.351 (Beta) lineage in South Africa29–33, P.1 (Gamma) lineage in Brazil34, and B.1.617.2 (Delta) lineage in India35,36; while the B.1.617.1 (Kappa) variant was defined as a variant of interest (VOI)37–41.",PMC8688474
B.1.617.2,"A number of SARS-CoV-2 lineages were defined as variants of concerns (VOCs) by the World Health Organization (WHO), including the B.1.1.7 (Alpha) lineage that arose in the UK26–30, B.1.351 (Beta) lineage in South Africa29–33, P.1 (Gamma) lineage in Brazil34, and B.1.617.2 (Delta) lineage in India35,36; while the B.1.617.1 (Kappa) variant was defined as a variant of interest (VOI)37–41.",PMC8688474
B.1.351,"A number of SARS-CoV-2 lineages were defined as variants of concerns (VOCs) by the World Health Organization (WHO), including the B.1.1.7 (Alpha) lineage that arose in the UK26–30, B.1.351 (Beta) lineage in South Africa29–33, P.1 (Gamma) lineage in Brazil34, and B.1.617.2 (Delta) lineage in India35,36; while the B.1.617.1 (Kappa) variant was defined as a variant of interest (VOI)37–41.",PMC8688474
B.1.617.1,"A number of SARS-CoV-2 lineages were defined as variants of concerns (VOCs) by the World Health Organization (WHO), including the B.1.1.7 (Alpha) lineage that arose in the UK26–30, B.1.351 (Beta) lineage in South Africa29–33, P.1 (Gamma) lineage in Brazil34, and B.1.617.2 (Delta) lineage in India35,36; while the B.1.617.1 (Kappa) variant was defined as a variant of interest (VOI)37–41.",PMC8688474
B.1.617.2,"SARS-CoV-2 genomic diversity profiles were also examined from daily sampling of culture experiments for three SARS-CoV-2 variants (Lineage A, B.1.351, and B.1.617.2) cultured in VeroE6 C1008 cells (n = 33)..

ISNVs were detected in 83% (19/23) of the mild cohort cases and 100% (16/16) of the severe cohort cases.",PPR425039
B.1.351,"SARS-CoV-2 genomic diversity profiles were also examined from daily sampling of culture experiments for three SARS-CoV-2 variants (Lineage A, B.1.351, and B.1.617.2) cultured in VeroE6 C1008 cells (n = 33)..

ISNVs were detected in 83% (19/23) of the mild cohort cases and 100% (16/16) of the severe cohort cases.",PPR425039
B.6,"The majority of cases were designated to lineage B.1.617.2 or Delta VOC (n=20, cases; P601, P603, P608, P611, P612, P614, P615, P622, P624, P626, P629, P604, P606, P618, P620, P621, PG27, P628), followed by B.1 (n=13 cases P0332, P0570, P0495, P0676, P1384, P1434, and P1494), D.2 genomes (n=11, cases; P0340, P0341, P0417, P0642, P0858, P1149, P2099, P2152, P1498 and P1551) and B.6 (n=4, case P0105).",PPR425039
D.2,"The majority of cases were designated to lineage B.1.617.2 or Delta VOC (n=20, cases; P601, P603, P608, P611, P612, P614, P615, P622, P624, P626, P629, P604, P606, P618, P620, P621, PG27, P628), followed by B.1 (n=13 cases P0332, P0570, P0495, P0676, P1384, P1434, and P1494), D.2 genomes (n=11, cases; P0340, P0341, P0417, P0642, P0858, P1149, P2099, P2152, P1498 and P1551) and B.6 (n=4, case P0105).",PPR425039
B.1,"The majority of cases were designated to lineage B.1.617.2 or Delta VOC (n=20, cases; P601, P603, P608, P611, P612, P614, P615, P622, P624, P626, P629, P604, P606, P618, P620, P621, PG27, P628), followed by B.1 (n=13 cases P0332, P0570, P0495, P0676, P1384, P1434, and P1494), D.2 genomes (n=11, cases; P0340, P0341, P0417, P0642, P0858, P1149, P2099, P2152, P1498 and P1551) and B.6 (n=4, case P0105).",PPR425039
B.1.1,"Single genomes from lineage A.2.2 (case P1727) lineage A genome (case P1811) and lineage B.1.1 (P1020) (Figure 1, Table 1).",PPR425039
A.2.2,"Single genomes from lineage A.2.2 (case P1727) lineage A genome (case P1811) and lineage B.1.1 (P1020) (Figure 1, Table 1).",PPR425039
B.1.617,"Group’s three to five were all in lineage B.1.617, and of those groups, groups four and five had no shared iSNVs between cases.",PPR425039
B.1.1.7,"The evolutionary rate of SARS-CoV-2 has been estimated at 1.1 x 10-3 substitutions/site/year (Smith et al., 2014, Day et al., 2020), however, some variants, such as Alpha (Lineage B.1.1.7) and Delta (Lineage B.1.617.2) have developed a higher percentage of nucleotide changes (Duchene et al., 2020, Rambaut, 2020).",PPR425039
B.1.1.33,"(2021)GreeceApr/2020-May/2020Raw sewage, Sludge samplesWTP116/29 (55%)1.6 × 106 to 3.2 × 106 (g.c./L)BViral loads in sewage samples showed a declining trend up to undetectable levels in line with the very low number of infections and hospital admissions in area under observation49Prado, (2020)BrazilApr/2020Raw sewageWTP, hospital, sewers network125/12 (42%)Not reportedASARS-CoV-2 RNA detected prevalently in samples from areas with a higher number of reported COVID-19 casesSARS-CoV-2 RNA was also detected in one sample from an area not yet reached by the outbreak50Prado, (2021)BrazilApr/2020-Aug/2020Raw sewageWTP2188/223 (84.3%)6.3 × 105 to 5.0 × 106 (g.c./L)A, DSARS-CoV-2 RNA was detected in sewage in a community where no COVID-19 cases had been reportedSequencing of SARS-CoV-2 in sewage showed three strains sharing the same nucleotide mutations (clade G, B.1.1.33), which were also observed in clinical strains circulating in the same area during the study period51Randazzo, (2020a)SpainFeb/2020-Apr/2020Raw sewageWTP312/15 (83%)1.65 × 105 to 9.77 × 105 (g.c./L)ASARS-CoV-2 RNA was consistently detected in wastewater samples taken in late February 2020, when COVID-19 cases in that region were only incipientRT-qPCR signal in wastewaters increased and reached a plateau faster than reported casesStrong indication that SARS-CoV-2 was undergoing community transmission earlier than previously believed52Randazzo, (2020b)SpainMar/2020-Apr/2020Raw sewageWTP635/42 (84%)2.5 × 105 (g.c./L)ASARS-CoV-2 RNA was detected in wastewater samples in low prevalence municipalities, 12–16 days before COVID-19 cases were reported53Rimoldi, (2020)ItalyApr/2020Raw sewageWTP34/8 (50%)Not reportedDA SARS-CoV-2 genome from a sewage sample collected in Northern Italy in April 2020 was similar to a clinical sampe from the same region54Saguti, (2021)SwedenFeb/2020-Jul/2020Raw sewageWTP518/21 (86%)7.9 × 103 to 1.8 × 106 (g.c./L)AAnalysis of multiple WTPs in one city displayed differences in the local incidence of SARS-CoV-2, thus enabling the detection of local outbreaksSARS-CoV-2 RNA peaks in wastewater preceded the peaks of COVID-19 hospitalized patients by 3–4 weeks55Saththasivam, (2021)QatarJun/2020-Aug/2020Raw sewageWTP543/43 (100%)7.8 × 103 to 5.4 × 105 (g.c./L)B, CFirst report of SARS-CoV-2 RNA in wastewaters in QatarThe trend of PCR Ct values in wastewater samples mirrored the number of new daily positive casesThe number of infected subjects was estimated by mathematical model using viral concentrations of wastewater samples; the estimated number was significantly higher than the officially reported ceses56Sharma et al.",PMC8561373
B.1.1.7,"Alpha, Beta, Gamma, and Delta (B.1.1.7, B.1.351, P.1, and B.1.617.2 pango lineages, respectively, recently relabelled by the WHO) are the so-called variants of concern for which clear evidence is available indicating a significant impact on transmissibility, severity and/or immunity that is likely to affect the epidemiological situation (European Centre for Disease Prevention and Control 2021).",PMC8561373
P.1,"Alpha, Beta, Gamma, and Delta (B.1.1.7, B.1.351, P.1, and B.1.617.2 pango lineages, respectively, recently relabelled by the WHO) are the so-called variants of concern for which clear evidence is available indicating a significant impact on transmissibility, severity and/or immunity that is likely to affect the epidemiological situation (European Centre for Disease Prevention and Control 2021).",PMC8561373
B.1.617.2,"Alpha, Beta, Gamma, and Delta (B.1.1.7, B.1.351, P.1, and B.1.617.2 pango lineages, respectively, recently relabelled by the WHO) are the so-called variants of concern for which clear evidence is available indicating a significant impact on transmissibility, severity and/or immunity that is likely to affect the epidemiological situation (European Centre for Disease Prevention and Control 2021).",PMC8561373
B.1.351,"Alpha, Beta, Gamma, and Delta (B.1.1.7, B.1.351, P.1, and B.1.617.2 pango lineages, respectively, recently relabelled by the WHO) are the so-called variants of concern for which clear evidence is available indicating a significant impact on transmissibility, severity and/or immunity that is likely to affect the epidemiological situation (European Centre for Disease Prevention and Control 2021).",PMC8561373
A.2.2,"Our simulations showed that one infected agent with the ancestral (A.2.2) variant has a 14% chance of crossing a threshold of sustained community transmission (SCT) (i.e., > 5 infections per day, more than 3 days in a row), assuming no change in the prevailing preventative and counteracting policies.",PPR361607
B.1.617.2,"However, one agent carrying the alpha (B.1.1.7) variant has a 43% chance of crossing the same threshold; a threefold increase with respect to the ancestral strain; while, one agent carrying the delta (B.1.617.2) variant has a 60% chance of the same threshold, a fourfold increase with respect to the ancestral strain.",PPR361607
B.1.1.7,"However, one agent carrying the alpha (B.1.1.7) variant has a 43% chance of crossing the same threshold; a threefold increase with respect to the ancestral strain; while, one agent carrying the delta (B.1.617.2) variant has a 60% chance of the same threshold, a fourfold increase with respect to the ancestral strain.",PPR361607
B.1.617.1,"Variants such as the B.1.617.1 (or kappa) and B.1.617.2 (or delta) lineages that emerged in India have been shown to be up to 2.5 times more transmissible than the ancestral strain [9, 11–13].",PPR361607
V.2,Variants with minor allele frequency less than 0.005 as per GnomAD v.2 were filtered and those located in genes known to be associated with cataract development as per Cat-Map database were given a priority for further evaluation.,PMC7705438
C.14,"We identified one previously reported (c.2729 C>T), five novel missense (c.3029 A>G, c.1738-1739 del ins TT, c.1163 G>A, c.3058 C>T, c.329 G>A) and two novel nonsense (c.1213 delT fs*, c.14 C>A fs*) mutations.",PMC7705438
V.1,"All variants were reclassified according to ACMG/AMP guidelines (both applying the TP53 rule specifications (v.1) provided by the ClinGen TP53 Expert Panel, and automatically using PathoMan)..",PMC7705438
C.38,"Results: We found 8 mutations in this patient in 2018 when he found the cancer and the mutation sites were APC c.3189 delT (50.81%), TP53 c.339 delC (55.46%), KRAS c.38 G>A (39.38%), EYS c.157 T>G (0.38%), KIT c.147 C>T (0.31%), PHACTR1 c.760 C>G (0.20%), CSMD3 c.837 T>G (0.08%) and SLITRK4 c.329 A>C (0.05%).",PMC7705438
